Tirzepatide

Short Description:

API’s Name CAS No. US DMF Patent Expiry Date (US) Current status
Tirzepatide  2023788-19-2  Jan.05, 2036 Pilot Production

 

[Indication]

1. As an adjunct to diet and exercise, to improve glycemic control in adults with type 2 diabetes mellitus.

2. As an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of ≥30 kg/m² (obesity) or ≥27 kg/m² (overweight) with at least one weight-related comorbidity.

3. For the treatment of moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity.


Product Detail

Product Tags


  • Previous:
  • Next:

  • Write your message here and send it to us